Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Cellectis S.A.NASDAQ: CLLS

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$22.55M, compared with -$11.29M a year earlier. Trailing-twelve-month EBITDA was -$51.11M.

Context

  • EBITDA amounted to 54.6% of revenue in FY2025, up 31.8 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of -$95.51M (-139.7%) for the fiscal year ending Dec 2026, a step up from the -321.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.55M-15.0% QoQ
Last fiscal yearDec 2025
-$39.85M-321.1% YoY
LTMMar 2026
-$51.11M-57.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.8%-20.4%+79.4 pp
1 year-321.1%-139.7%+181.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(39.85M) USD
Year-over-year change
-321.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -57.3% is the 9th highest of 10, against a peer median of -16.9%.
  • EBITDA amounts to 75.1% of revenue for CLLS, versus a peer median of 2034.0%.
CLLS Competitors
EBITDA for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026-$5.14M USD+92.4%—2.4%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$25.22M USD+54.6%——
MREOMereo BioPharma Group plcLTM Mar 2026-$39.29M USD+13.4%—7858.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026-$44.93M USD-42.6%——
CLLSCellectis S.A.LTM Mar 2026-$51.11M USD-57.3%—75.1%
ACIUAC Immune S.A.LTM Mar 2026-CHF 64.45M CHF-29.6%—1740.8%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$71.29M USD-16.9%——
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M USD——8478.5%
KRROKorro Bio, Inc.LTM Mar 2026-$78.15M USD+14.5%—2034.0%
DBVTDBV Technologies S.A.LTM Mar 2026-$159.48M USD-49.1%——
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$165.68M USD-74.6%——
Peer median (excluding CLLS) —-16.9%—2034.0%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.